论文部分内容阅读
目的:观察不同剂量瑞舒伐他汀对急性脑梗死血浆炎症因子的影响及临床疗效。方法:80例急性脑梗死患者分为观察组和对照组各40例。两组患者均予以控制颅内压、维持血压、血糖、抗血小板聚集、改善脑微循环等基础治疗,同时,对照组口服瑞舒伐他汀片10 mg,qd;观察组口服瑞舒伐他汀片20mg·L~(-1)。,qd。连用2周。观察两组患者治疗前后血浆炎症因子hs-CRP、IL-6和IL-8水平,比较两组临床疗效及药品不良反应发生情况。结果:两组患者血浆hs-CRP、IL-6和IL-8水平均较治疗前明显下降(P<0.05或和P<0.01),且观察组下降幅度较对照组更明显(P<0.05);观察组临床总有效率明显高于对照组(P<0.05);治疗期间两组患者均未发生药品不良反应。结论:高剂量瑞舒伐他汀治疗急性脑梗死可提高疗效,安全性较好,与降低血浆炎症因子hs-CRP、IL-6和IL-8水平密切相关。
Objective: To observe the effects of different doses of rosuvastatin on plasma inflammatory factors in acute cerebral infarction and its clinical efficacy. Methods: 80 patients with acute cerebral infarction were divided into observation group and control group, 40 cases each. Both groups were controlled intracranial pressure, blood pressure, blood glucose, anti-platelet aggregation, improve brain microcirculation and other basic treatment, while the control group oral rosuvastatin tablets 10 mg qd; observation group oral rosuvastatin tablets 20mg · L -1. , qd. For two weeks. The levels of plasma inflammatory cytokines hs-CRP, IL-6 and IL-8 before and after treatment were observed in both groups. The clinical efficacy and adverse drug reactions were compared between the two groups. Results: The levels of plasma hs-CRP, IL-6 and IL-8 in two groups were significantly lower than those before treatment (P <0.05 or P <0.01), and the decrease in the observation group was more significant than that in the control group . The total clinical effective rate in the observation group was significantly higher than that in the control group (P <0.05). No adverse drug reactions occurred in both groups during the treatment period. Conclusions: High-dose rosuvastatin can improve the curative effect of acute cerebral infarction and its safety is better. It is closely related to the decrease of plasma inflammatory factors hs-CRP, IL-6 and IL-8.